H.C. Wainwright analyst Andrew Fein reiterated a Hold rating on Eloxx Pharmaceuticals (ELOX) today and set a price target of $3.00. The company’s shares closed last Monday at $3.45, close to its 52-week low of $2.82.
According to TipRanks.com, Fein is a 5-star analyst with an average return of 10.3% and a 43.9% success rate. Fein covers the Healthcare sector, focusing on stocks such as DBV Technologies SA – American, Constellation Pharmaceuticals, and Proteostasis Therapeutics.
Currently, the analyst consensus on Eloxx Pharmaceuticals is a Moderate Buy with an average price target of $8.50.
See today’s analyst top recommended stocks >>
Based on Eloxx Pharmaceuticals’ latest earnings release for the quarter ending December 31, the company reported a quarterly GAAP net loss of $11.63 million. In comparison, last year the company had a GAAP net loss of $14.03 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Eloxx Pharmaceuticals, Inc. engages in the development of novel ribonucleic acid modulating drug candidates. The firm focuses on the the formulation of medicines to treat rare and ultra-rare premature stop codon diseases. It operates through the United States and Israel geographical segments.
